Findings in Fluorescein Angiography and Optical Coherence Tomography after Intravitreal Bevacizumab in Type 2 Idiopathic Macular Telangiectasia

Peter Charbel Issa, Frank G. Holz, Hendrik P N Scholl

Research output: Contribution to journalArticle

Abstract

Purpose: To report the short-term effects of intravitreal bevacizumab in patients with type 2 idiopathic macular telangiectasia (IMT). Design: Noncomparative, interventional, retrospective case series. Participants: Seven eyes of 6 patients with type 2 IMT were studied. Methods: Patients received 2 doses of intravitreal bevacizumab (1.5 mg) at 4-week intervals. Serial examinations included standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity (VA), fluorescein angiography, and optical coherence tomography (OCT). Main Outcome Measures: Assessments of OCT retinal thickness, angiographic characteristics, and VA were performed at baseline and at 4 and 8 weeks after the initial treatment. Results: A mean increase in VA of 8 ETDRS letters at 8 weeks was found (P

Original languageEnglish (US)
Pages (from-to)1736-1742
Number of pages7
JournalOphthalmology
Volume114
Issue number9
DOIs
StatePublished - Sep 2007
Externally publishedYes

Fingerprint

Telangiectasis
Fluorescein Angiography
Optical Coherence Tomography
Visual Acuity
Diabetic Retinopathy
Outcome Assessment (Health Care)
Therapeutics
Bevacizumab

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Findings in Fluorescein Angiography and Optical Coherence Tomography after Intravitreal Bevacizumab in Type 2 Idiopathic Macular Telangiectasia. / Issa, Peter Charbel; Holz, Frank G.; Scholl, Hendrik P N.

In: Ophthalmology, Vol. 114, No. 9, 09.2007, p. 1736-1742.

Research output: Contribution to journalArticle

Issa, Peter Charbel ; Holz, Frank G. ; Scholl, Hendrik P N. / Findings in Fluorescein Angiography and Optical Coherence Tomography after Intravitreal Bevacizumab in Type 2 Idiopathic Macular Telangiectasia. In: Ophthalmology. 2007 ; Vol. 114, No. 9. pp. 1736-1742.
@article{f494e1cc82a848c599583478e1f723cf,
title = "Findings in Fluorescein Angiography and Optical Coherence Tomography after Intravitreal Bevacizumab in Type 2 Idiopathic Macular Telangiectasia",
abstract = "Purpose: To report the short-term effects of intravitreal bevacizumab in patients with type 2 idiopathic macular telangiectasia (IMT). Design: Noncomparative, interventional, retrospective case series. Participants: Seven eyes of 6 patients with type 2 IMT were studied. Methods: Patients received 2 doses of intravitreal bevacizumab (1.5 mg) at 4-week intervals. Serial examinations included standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity (VA), fluorescein angiography, and optical coherence tomography (OCT). Main Outcome Measures: Assessments of OCT retinal thickness, angiographic characteristics, and VA were performed at baseline and at 4 and 8 weeks after the initial treatment. Results: A mean increase in VA of 8 ETDRS letters at 8 weeks was found (P",
author = "Issa, {Peter Charbel} and Holz, {Frank G.} and Scholl, {Hendrik P N}",
year = "2007",
month = "9",
doi = "10.1016/j.ophtha.2007.03.079",
language = "English (US)",
volume = "114",
pages = "1736--1742",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Findings in Fluorescein Angiography and Optical Coherence Tomography after Intravitreal Bevacizumab in Type 2 Idiopathic Macular Telangiectasia

AU - Issa, Peter Charbel

AU - Holz, Frank G.

AU - Scholl, Hendrik P N

PY - 2007/9

Y1 - 2007/9

N2 - Purpose: To report the short-term effects of intravitreal bevacizumab in patients with type 2 idiopathic macular telangiectasia (IMT). Design: Noncomparative, interventional, retrospective case series. Participants: Seven eyes of 6 patients with type 2 IMT were studied. Methods: Patients received 2 doses of intravitreal bevacizumab (1.5 mg) at 4-week intervals. Serial examinations included standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity (VA), fluorescein angiography, and optical coherence tomography (OCT). Main Outcome Measures: Assessments of OCT retinal thickness, angiographic characteristics, and VA were performed at baseline and at 4 and 8 weeks after the initial treatment. Results: A mean increase in VA of 8 ETDRS letters at 8 weeks was found (P

AB - Purpose: To report the short-term effects of intravitreal bevacizumab in patients with type 2 idiopathic macular telangiectasia (IMT). Design: Noncomparative, interventional, retrospective case series. Participants: Seven eyes of 6 patients with type 2 IMT were studied. Methods: Patients received 2 doses of intravitreal bevacizumab (1.5 mg) at 4-week intervals. Serial examinations included standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity (VA), fluorescein angiography, and optical coherence tomography (OCT). Main Outcome Measures: Assessments of OCT retinal thickness, angiographic characteristics, and VA were performed at baseline and at 4 and 8 weeks after the initial treatment. Results: A mean increase in VA of 8 ETDRS letters at 8 weeks was found (P

UR - http://www.scopus.com/inward/record.url?scp=34548205365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548205365&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2007.03.079

DO - 10.1016/j.ophtha.2007.03.079

M3 - Article

C2 - 17822979

AN - SCOPUS:34548205365

VL - 114

SP - 1736

EP - 1742

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 9

ER -